Survodutide
Same-day shipping — Ships next business day, cutoff 3 PM ET.
≥99% purity verified by independent HPLC and mass spectrometry (MS) through Janoshik Analytical. Intended for laboratory research use only; not for human consumption, diagnosis, or treatment. View transparency report Compliance PDFs
Documentation & standards
- How to Read a Peptide Certificate of Analysis (COA)
- Peptide Storage and Handling: Temperature, Light and Stability
- Research-Use-Only Compliance: What the Label Obligates
Dual GLP-1/glucagon receptor agonist studied in metabolic and energy regulation research.
Mix and match any items — discount applies automatically at checkout.
Reminder email when it's time to reorder. No card on file. Cancel anytime from your account — or email support@aresresearchlab.com.
Batch transparency
- Batch / lot
- Released with your order
- Testing lab
- Janoshik Analytical
- Purity (HPLC)
- ≥99% target spec
- Identity (MS)
- Available on request
- Report issued
- Available on request
- Full PDF report
- By request
Every request returns a reference number and a live status page. See all published batch records →
For laboratory research use only — not for human or veterinary use.
Earn 64 loyalty points on this purchase · 100 pts = $5 off
Create a Research Account to unlock full batch data, COAs, and priority releases.
Intended strictly for research and laboratory use only. Not for human consumption.
About Survodutide
Third-party purity testing available upon request.
Research Classification
Storage Information
Survodutide Purity & COA Verification
For laboratory research use only. Not for human consumption, diagnosis, or treatment.
Survodutide — Compound Information & Scientific Literature
Reference data for laboratory personnel: molecular identity, storage and stability handling, our analytical testing panel, and peer-reviewed literature indexed on PubMed.
Molecular Profile
| Compound | Survodutide |
|---|---|
| Molecule type | GLP-1/GCG Dual Agonist |
| Class | GLP-1/GCG Dual Agonist |
| Catalog category | Metabolic Research |
| Physical format | Lyophilized vial |
Handling Reference
-20 °C, protected from light and moisture
24 months from date of manufacture in the sealed vial
2-8 °C (refrigerated), do not freeze after reconstitution
Stability studied out to approximately 28 days under continuous refrigeration
Analytical Testing Panel
Verified by Janoshik Analytical — full panel, every batch. Second independent lab confirmation is being added batch by batch.
Quantifies the main peak against related-substance peaks, so the stated purity percentage is measured rather than assumed.
Every Survodutide lot passes all 8 stages before it is released. Expand a stage to see the method and why we run it.
- Method on the COARP-HPLC (UV 214 nm)Why Ares runs it
Quantifies the main peak against related-substance peaks, so the stated purity percentage is measured rather than assumed.
- Method on the COAQuantitative HPLC mass/concentration assayWhy Ares runs it
Confirms the vial actually contains the labeled amount — purity alone says nothing about how much material is in the vial.
- Method on the COAMass Spectrometry (ESI-MS)Why Ares runs it
Confirms the measured molecular mass matches the declared compound — the check that catches a mislabeled or substituted vial.
- Method on the COAICP-MSWhy Ares runs it
Screens for elemental contaminants carried over from synthesis, reagents, or packaging.
- Method on the COAMembrane filtration, USP <71> methodologyWhy Ares runs it
Checks the finished lyophilized vial for microbial growth after fill and closure.
- Method on the COALAL assay (kinetic chromogenic)Why Ares runs it
Measures bacterial endotoxin load, a contamination marker that purity testing alone will not reveal.
- Method on the COAIndependent batch review against release specificationWhy Ares runs it
Ties the analytical numbers back to the paperwork — the lot you receive is the lot on the certificate.
- Method on the COALC-MS/MS targeted screenWhy Ares runs it
A contamination check most research suppliers never run, and the reason we run it on every batch regardless of compound.
PASS reflects the batch release standard every lot must meet before it ships. Per-lot results are published on that lot's Certificate of Analysis.
Peer-Reviewed References
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW et al. · The lancet. Diabetes & endocrinology, 2024 · PMID 38330987
View sourceDose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Blüher M et al. · Diabetologia, 2024 · PMID 38095657
View sourceEfficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
Lawitz EJ et al. · Journal of hepatology, 2024 · PMID 38857788
View sourceA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal AJ et al. · The New England journal of medicine, 2024 · PMID 38847460
View sourceBaseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
Wharton S et al. · Diabetes, obesity & metabolism, 2026 · PMID 41216778
View source
References are listed for literature-identification purposes only. Ares Research is not affiliated with the authors, journals, or institutions cited.
This material is supplied for laboratory and research use only. It is not for human or veterinary use, and it is not a drug, food, or cosmetic. These statements have not been evaluated by the Food and Drug Administration. No information on this page is intended to diagnose, treat, cure, or prevent any condition.
Read the Survodutide research
Research guide on Survodutide (BI 456906): dual GLP-1 / glucagon receptor agonism, MASLD and metabolic literature, and the documented side-effect profile.
Read article →Published benefits, side effects, and semaglutide/Retatrutide comparisons for tirzepatide — the GLP-1/GIP dual agonist that established GIP-receptor co-agonism as a productive metabolic axis.
Read article →Published benefits, side effects, and tirzepatide/semaglutide comparisons for Retatrutide — the investigational GLP-1/GIP/glucagon triple agonist with the largest body-weight reductions reported for any non-surgical incretin pharmacotherapy.
Read article →Reference dose tiers, titration ladder, reconstitution math, and weekly-injection scheduling from the published survodutide (GLP-1/glucagon dual agonist) research record.
Read article →How Ares compares for Survodutide
Independent, documentation-first breakdowns of the vendors researchers most often ask about for this compound. COA verification, US shipping, and sourcing transparency, side by side.
Frequently bought together
Curated complements for this compound — researchers most often pair it with these.
Research Use Disclaimer
Researcher Reviews
Sign in with the account that placed your order to leave a verified review.
Ask the Lab
No public questions yet — be the first to ask.
All testing documentation and COA data are provided for laboratory research use only and are not intended to support human consumption, diagnostic, or therapeutic use.
